Literature DB >> 30701359

6-Methoxyquinoline complexes as lung carcinoma agents: induction of oxidative damage on A549 monolayer and multicellular spheroid model.

J F Cadavid-Vargas1,2, C Villa-Pérez1, M C Ruiz1,2, I E León1, G C Valencia-Uribe3, D B Soria1, S B Etcheverry1,2, A L Di Virgilio4,5.   

Abstract

The aim of this work was to study the antitumor effects and the mechanisms of toxic action of a series of 6-methoxyquinoline (6MQ) complexes in vitro. The Cu(II) and Zn(II) complexes (Cu6MQ and Zn6MQ) are formulated as M(6MQ)2Cl2; the Co(II) and Ag(I) compounds (Co6MQ and Ag6MQ) are ionic with formulae [Ag(6MQ)2]+NO3- and H(6MQ)+[Co(6MQ)Cl3]- (where H(6MQ)+ is the protonated ligand). We found that the copper complex, outperformed the Co(II), Zn(II) and Ag(I) complexes with a lower IC50 (57.9 µM) in A549 cells exposed for 24 h. Cu6MQ decreased cell proliferation and induced oxidative stress detected with H2DCFDA at 40 µM, which reduces GSH/GSSG ratio. This redox imbalance induced oxidative DNA damage revealed by the Micronucleus test and the Comet assay, which turned into a cell cycle arrest at G2/M phase and induced apoptosis. In multicellular spheroids, the IC50 values tripled the monolayer model (187.3 µM for 24 h). At this concentration, the proportion of live/dead cells diminished, and the spheroids could not proliferate or invade. Although Zn6MQ also decreased GSH/GSSG ratio from 200 µM and the cytotoxicity is related to oxidative stress, the induction of the hydrogen peroxide levels only doubled the control value. Zn6MQ induced S phase arrest, which relates with the increased micronucleus frequency and with the induction of necrosis. Finally, our results reveal a synergistic activity with a 1:1 ratio of both complexes in the monolayer and multicellular spheroids.

Entities:  

Keywords:  6-Methoxyquinoline complexes; A549 cells; Lung carcinoma; Multicellular spheroid model; Oxidative damage

Mesh:

Substances:

Year:  2019        PMID: 30701359     DOI: 10.1007/s00775-019-01644-7

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  55 in total

1.  Inhibition of human DNA ligase I activity by zinc and cadmium and the fidelity of ligation.

Authors:  S W Yang; F F Becker; J Y Chan
Journal:  Environ Mol Mutagen       Date:  1996       Impact factor: 3.216

2.  A reliable tool to determine cell viability in complex 3-d culture: the acid phosphatase assay.

Authors:  Juergen Friedrich; Wolfgang Eder; Juana Castaneda; Markus Doss; Elisabeth Huber; Reinhard Ebner; Leoni A Kunz-Schughart
Journal:  J Biomol Screen       Date:  2007-10

Review 3.  Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?

Authors:  Christos Damaskos; Ioannis Tomos; Nikolaos Garmpis; Anna Karakatsani; Dimitrios Dimitroulis; Anna Garmpi; Eleftherios Spartalis; Christos F Kampolis; Eleni Tsagkari; Angeliki A Loukeri; Georgios-Antonios Margonis; Michael Spartalis; Nikolaos Andreatos; Dimitrios Schizas; Stefania Kokkineli; Efstathios A Antoniou; Afroditi Nonni; Gerasimos Tsourouflis; Konstantinos Markatos; Konstantinos Kontzoglou; Alkiviadis Kostakis; Periklis Tomos
Journal:  Anticancer Res       Date:  2018-01       Impact factor: 2.480

4.  Zinc complex of tryptophan appended 1,4,7,10-tetraazacyclododecane as potential anticancer agent: Synthesis and evaluation.

Authors:  Anupriya Adhikari; Neelam Kumari; Manish Adhikari; Nitin Kumar; Anjani K Tiwari; Abha Shukla; Anil K Mishra; Anupama Datta
Journal:  Bioorg Med Chem       Date:  2017-04-29       Impact factor: 3.641

5.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

6.  Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.

Authors:  Weiwei Yu; Weiqiang Lu; Guoliang Chen; Feixiong Cheng; Hui Su; Yihua Chen; Mingyao Liu; Xiufeng Pang
Journal:  Br J Pharmacol       Date:  2017-08-24       Impact factor: 8.739

7.  Controlling tumor growth by modulating endogenous production of reactive oxygen species.

Authors:  Alexis Laurent; Carole Nicco; Christiane Chéreau; Claire Goulvestre; Jérôme Alexandre; Arnaud Alves; Eva Lévy; Francois Goldwasser; Yves Panis; Olivier Soubrane; Bernard Weill; Frédéric Batteux
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

Review 8.  Lung cancer: current therapies and new targeted treatments.

Authors:  Fred R Hirsch; Giorgio V Scagliotti; James L Mulshine; Regina Kwon; Walter J Curran; Yi-Long Wu; Luis Paz-Ares
Journal:  Lancet       Date:  2016-08-27       Impact factor: 79.321

9.  The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

Authors:  Lisa M Butler; Xianbo Zhou; Wei-Sheng Xu; Howard I Scher; Richard A Rifkind; Paul A Marks; Victoria M Richon
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-20       Impact factor: 11.205

10.  Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms.

Authors:  L Wang; H Li; Y Ren; S Zou; W Fang; X Jiang; L Jia; M Li; X Liu; X Yuan; G Chen; J Yang; C Wu
Journal:  Cell Death Dis       Date:  2016-01-21       Impact factor: 8.469

View more
  1 in total

1.  Enhanced antitumor effect of L-buthionine sulfoximine or ionizing radiation by copper complexes with 2,2´-biquinoline and sulfonamides on A549 2D and 3D lung cancer cell models.

Authors:  J F Cadavid Vargas; C Villa Perez; D B Soria; A Guerci; A L Di Virgilio
Journal:  J Biol Inorg Chem       Date:  2022-03-05       Impact factor: 3.358

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.